Continuous glucose monitoring in ICU

ACTRN12612000130864

Status	RECRUITING
Sponsor	University of Canterbury
Enrollment	80 participants

Plain Language Summary

This study is testing better ways to monitor blood sugar levels in critically ill patients in the intensive care unit (ICU). Keeping blood sugar in a safe range is very important for ICU patients, but it can be difficult and the risk of dangerously low blood sugar is a concern. The study will look at how accurate bedside glucose meters are, and also test small continuous glucose monitoring devices that check sugar levels every five minutes automatically. Participating patients will have up to three of these small devices placed on the skin at the same time.

You may be eligible if:
- You are 16 years of age or older
- You are an ICU patient receiving intensive insulin therapy to control blood sugar
- You are expected to remain in the ICU for at least 3 to 5 days
- You have a platelet count above 30,000 per microliter

You may NOT be eligible if:
- You are not expected to survive your ICU stay
- Informed consent cannot be obtained
- You have skin conditions at the intended device insertion sites
- You are pregnant
- You are receiving treatment that includes Hydroxyurea

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- (i) The participant is treated using intensive insulin therapy, (ii) Expected to remain in ICU for at least 3-5 days, and (iii) a platelet count > 30,000 per micro-litre

Exclusion (1)

- (i) Not expected to survive intensive care, (ii) Unable to obtain consent, (iii) Any conditions that might preclude the use of CGM such as skin lesions affecting proposed insertion areas, (iv) Lack of clinical equipoise, (v) Pregnant subjects, and (vi) subject is receiving treatment that includes Hydroxyurea.

Locations (1 total)

Canterbury, New Zealand